Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
A crosstalk established between tumor microenvironment and tumor cells leads to contribution or inhibition of tumor progression. Mesenchymal stem cells (MSCs) are critical cells that fundamentally participate in modulation of the tumor microenvironment, and have been reported to be able to regulate and determine the final destination of tumor cell. Conflicting functions have been attributed to the activity of MSCs in the tumor microenvironment; they can confer a tumorigenic or anti-tumor potential to the tumor cells. Nonetheless, MSCs have been associated with a potential to modulate the tumor microenvironment in favouring the suppression of cancer cells, and promising results have been reported from the preclinical as well as clinical studies. Among the favourable behaviours of MSCs, are releasing mediators (like exosomes) and their natural migrative potential to tumor sites, allowing efficient drug delivering and, thereby, efficient targeting of migrating tumor cells. Additionally, angiogenesis of tumor tissue has been characterized as a key feature of tumors for growth and metastasis. Upon introduction of first anti-angiogenic therapy by a monoclonal antibody, attentions have been drawn toward manipulation of angiogenesis as an attractive strategy for cancer therapy. After that, a wide effort has been put on improving the approaches for cancer therapy through interfering with tumor angiogenesis. In this article, we attempted to have an overview on recent findings with respect to promising potential of MSCs in cancer therapy and had emphasis on the implementing MSCs to improve them against the suppression of angiogenesis in tumor tissue, hence, impeding the tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 1×
“Additionally, MSCs release chemokines, such as CXCR4 [30], CCL5, intracellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) [31, 32].”
BackgroundRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924 · cited 1×
“Paclitaxel (PTX) is an effective antitumor agents against cancer [51].”
BackgroundInduction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“Additionally, MSCs release chemokines, such as CXCR4 [30], CCL5, intracellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) [31, 32].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807 · cited 4×
“Although most of researches aiming to exert MSCs in cancer therapy have focused on the tumor MSC Mesenchymal stem cell, TNF tumor necrosis factor, IFN interferon, IL interleukin, SDF stromal cell-derived factor, MCP monocyte chemoattractant protein, GRO growth-regulated oncogene, TGF transforming growth factor, PGF pl…”
BackgroundInfluentialAdipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431 · cited 2×
“Additionally, MSCs engineered to express fused yeast cytosine deaminase:Uracil phosphoribosyl transferase (yCD::UPRT) with chemotherapeutic compound 5-fluorocytosine (5-FC) as a prodrug-yCD:UPRT-MSC/5– FC system in human colon cancer [47].”
BackgroundMesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo
Zhu, W., Xu, W., Jiang, R., Qian, H., Chen, M., Hu, J., Cao, W., Han, C., & Chen, Y. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.07.004 · Cited by 386 · cited 1×
“Additionally, MSCs were detected to promote the cancerous behaviour of tumor cells in ovarian cancer [38], colon cancer [39], and gastric cancer [40].”
BackgroundMcLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Hong, H. S., Lee, J., Lee, E., Kwon, Y. S., Lee, E., Ahn, W., Jiang, M. H., Kim, J. C., & Son, Y. (2009) · Nature Medicine · doi:10.1038/nm.1909 · Cited by 349 · cited 1×
“This factor of wound healing originates with migration toward inflammatory signals caused by the injured tissue [17].”
BackgroundQiao, L., Xu, Z.-L., Zhao, T.-J., Ye, L.-H., & Zhang, X.-D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.032 · Cited by 313
Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy
Ellis, L. M., & Hicklin, D. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5287 · Cited by 257
Mesenchymal Stromal Cells Promote Tumor Growth through the Enhancement of Neovascularization
Suzuki, K., Sun, R., Origuchi, M., Kanehira, M., Takahata, T., Itoh, J., Umezawa, A., Kijima, H., Fukuda, S., & Saijo, Y. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00157 · Cited by 244 · cited 1×
“MSCs have some adverse effect on tumor cells, such as differentiation of vascular endothelial cells in melanoma [27], enhancing the expansion of gastric cancer cell lines [28], inducing cancer stem cells (CSCs) that has been associated with increased metastasis, tumorigenesis, and recurrence of tumors [29].”
BackgroundThe growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo
Lu, Y.-R., Yuan, Y., Wang, X.-J., Wei, L.-L., Chen, Y.-N., Cong, C., Li, S.-F., Long, D., Tan, W.-D., Mao, Y.-Q., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.2.5296 · Cited by 225
Xu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
Razmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A.-R., & Ghaderi, A. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.005 · Cited by 116 · cited 4×
“Although most of researches aiming to exert MSCs in cancer therapy have focused on the tumor MSC Mesenchymal stem cell, TNF tumor necrosis factor, IFN interferon, IL interleukin, SDF stromal cell-derived factor, MCP monocyte chemoattractant protein, GRO growth-regulated oncogene, TGF transforming growth factor, PGF pl…”
BackgroundResultInfluential
Cited by
Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review
Margiana, R., Markov, A., Zekiy, A. O., Hamza, M. U., Al-Dabbagh, K. A., Al-Zubaidi, S. H., Hameed, N. M., Ahmad, I., Sivaraman, R., Kzar, H. H., et al. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03054-0 · Cited by 429
Self-citationMesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374
Zhidu, S., Ying, T., Rui, J., & Chao, Z. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03885-z · Cited by 162
Advancements and Challenges in Stem Cell Transplantation for Regenerative Medicine
Wei, L., Yan, W., Shah, W., Zhang, Z., Wang, M., Liu, B., Xue, Z., Cao, Y., Hou, X., Zhang, K., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35836 · Cited by 79
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
“171 For instance, Huang et al. 172 found that IL-6 secreted by MSCs can increase the secretion of endothelin-1 (ET-1) in human colorectal cancer cells, which induces the activation of Akt and ERK in endothelial cells, thereby enhancing their capacity for recruitment and angiogenesis to the tumor.”
Background
Metadata
- Authors
- Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V., & Ahmadi, M.
- Venue
- Cancer Cell International
- Published
- 2021-03-08
- Volume
- 21
- Issue
- 1
- Pages
- 158-158
- ISSN
- 1475-2867 (ISSN-L)
- OpenAlex
- W3135638864
- Cited by
- 70
- References
- 19
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.